Positive results for Rallybio newborn drug
New Haven’s Rallybio reported promising results in a Phase 1 study of its drug candidate RLYB212, designed for the prevention of a serious blood disease in fetuses...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
New Haven’s Rallybio reported promising results in a Phase 1 study of its drug candidate RLYB212, designed for the prevention of a serious blood disease in fetuses...
View this email in your browser Weekly Roundup – October 13, 2022 Thank you to LaunchBio for hosting the successful “Larger Than Life Science” program this week....
Pasithea Therapeutics, which focuses on treatments for central nervous system (CNS) disorders, has acquired AlloMek Therapeutics. AlloMek’s lead therapeutic candidate, CIP-137401, is a potential best-in-class macrocyclic mitogen-activated...
“The Arvinas” pizza is a collaboration between the restaurant BAR New Haven and Arvinas, a New Haven-based clinical-stage biopharmaceutical company developing targeted protein degradation therapeutics. When someone...
Connecticut Children’s has submitted a 345-page master plan to the Hartford Planning and Zoning Commission outlining a $280 million expansion that will reshape the hospital’s Hartford...
Yale New Haven Health has signed agreements to acquire two health systems from California-based Prospect Medical Holdings, including three hospitals and the health systems’ related businesses,...
“The Yale Faculty Innovation Award makes crystal clear to the entire Yale community that the university appreciates, recognizes, and celebrates faculty launching new startup companies,”...
View this email in your browser Weekly Roundup – October 6, 2022 ...
A clinical-stage nonprofit biotechnology company, Cure Rare Disease, has acquired its first laboratory space in Woodbridge. The organization will relocate its Boston headquarters to the 30,000-square-foot...
Enrich Therapeutics reports that the company had been awarded a 12-month Small Business Innovation Research (SBIR) research contract from the National Cancer Institute. The contract is...